PositiveID, developer of advanced technologies for diabetes management and rapid medical testing, as well as airborne bio-threat detection systems for America's homeland defense, today issued an update of the progress of the initial deployment of its FDA-cleared iglucose™ mobile health system for diabetes management.
The iglucose system collects and transmits stored data from a variety of FDA-cleared blood glucose meters to a secure database via wireless cellular technology. The system is currently being trialed by three large companies and was also recently trialed by a leading global pharmaceutical company.
"Many large organizations are currently trialing iglucose, from one of the largest health insurers in the U.S., to one of the largest consumer healthcare products companies in the world," William J. Caragol, PositiveID's chairman and CEO stated in the press release. "We are providing this progress report following our announcement last week that we made iglucose available for pre-order for consumers. We received a very positive response and therefore want to update the investor community as well as those with diabetes about our next steps."
Though the iglucose system is a wireless solution, it does not require the use of a cell phone or wireless plan, offering the user options for online access, e-mail, fax, or SMS text. The system was designed to enable individuals with diabetes to become more engaged in the self-management of their diabetes. The information obtained from glucometers can be composed into reports that can be shared with family members and healthcare professionals.
Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net